Ivanov Nikita I, Cowell Simon P, Brown Paula, Rennie Paul S, Guns Emma S, Cox Michael E
Prostate Research Centre at Vancouver General Hospital, University of British Columbia, 2660 Oak Street, Vancouver, BC, Canada V6T 1Z4.
Clin Nutr. 2007 Apr;26(2):252-63. doi: 10.1016/j.clnu.2007.01.002. Epub 2007 Mar 6.
BACKGROUND & AIMS: Lycopene has been credited with a number of health benefits including a decrease in prostate cancer risk. Our study investigates the molecular mechanism underlying anti-cancer activity of lycopene-based products in androgen-responsive (LNCaP) and androgen-independent (PC3) cells.
The effect of lycopene-based agents on prostate cancer growth and survival were examined using proliferation assays, bromodeoxyuridine incorporation and flow cytometric analysis of cellular DNA content. Biochemical effects of lycopene treatment were investigated by immunoblotting for changes in the absolute levels and phosphorylation states of cell cycle regulatory and signalling proteins.
LNCaP and PC3 cells treated with the lycopene-based agents undergo mitotic arrest, accumulating in G0/G1 phase. Immunoblot screening indicated that lycopene's antiproliferative effects are likely achieved through a block in G1/S transition mediated by decreased levels of cyclins D1 and E and cyclin dependent kinase 4 and suppressed Retinoblastoma phosphorylation. These responses correlated with decreased insulin-like growth factor-I receptor expression and activation, increased insulin-like growth factor binding protein 2 expression and decreased AKT activation. Exposure to lycopene at doses as low as 10 nM for 48 h induced a profound apoptotic response in LNCaP cells. In contrast PC3 cells were resistant to apoptosis at doses up to 1 microM.
Lycopene exposure can suppress phosphatidylinositol 3-kinase-dependent proliferative and survival signalling in androgen-responsive LNCaP and androgen-independent PC3 cells suggesting that the molecular mechanisms for the cytostatic and cytotoxic actions of lycopene involve induction of G0/G1 cell cycle arrest. This study supports further examination of lycopene as a potential agent for both the prevention and treatment of prostate cancer.
番茄红素具有多种健康益处,包括降低前列腺癌风险。我们的研究调查了基于番茄红素的产品在雄激素反应性(LNCaP)和雄激素非依赖性(PC3)细胞中抗癌活性的分子机制。
使用增殖试验、溴脱氧尿苷掺入和细胞DNA含量的流式细胞术分析,检测基于番茄红素的制剂对前列腺癌生长和存活的影响。通过免疫印迹法研究番茄红素处理的生化效应,检测细胞周期调节和信号蛋白的绝对水平和磷酸化状态的变化。
用基于番茄红素的制剂处理的LNCaP和PC3细胞发生有丝分裂停滞,积聚在G0/G1期。免疫印迹筛选表明,番茄红素的抗增殖作用可能是通过细胞周期蛋白D1和E、细胞周期蛋白依赖性激酶4水平降低介导的G1/S期转换阻滞以及视网膜母细胞瘤磷酸化受抑制来实现的。这些反应与胰岛素样生长因子-I受体表达和激活降低、胰岛素样生长因子结合蛋白2表达增加以及AKT激活降低相关。在LNCaP细胞中,低至10 nM的番茄红素剂量暴露48小时可诱导强烈的凋亡反应。相比之下,PC3细胞在高达1 microM的剂量下对凋亡具有抗性。
番茄红素暴露可抑制雄激素反应性LNCaP和雄激素非依赖性PC3细胞中磷脂酰肌醇3激酶依赖性增殖和存活信号,这表明番茄红素的细胞生长抑制和细胞毒性作用的分子机制涉及诱导G0/G1细胞周期停滞。本研究支持进一步研究番茄红素作为预防和治疗前列腺癌的潜在药物。